Zeitschrift für Kardiologie

, Volume 94, Issue 5, pp 336–342

Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis

  • V. Mitrovic
  • H. H. Klein
  • N. Krekel
  • J. Kreuzer
  • S. Fichtlscherer
  • A. Schirmer
  • W. D. Paar
  • C. W. Hamm
ORIGINAL PAPER

Summary

Some medications have been shown to produce reductions in hs-CRP levels after initiating therapy. Whereas the role of the renin-angiotensin system in the inflammatory process has been documented in more detail during the last few years, the impact of an ACE-inhibitor therapy on this process has not been fully understood so far. The aim of this study was to investigate the effect of a therapy with the angiotensin-converting enzyme (ACE) inhibitor ramipril on hs-CRP plasma concentrations in patients with atherosclerosis.

Methods and results

A total of 24 patients were enrolled in this prospective, uncontrolled, open-label multicenter study. Inclusion criteria were documented atherosclerosis, baseline high-sensitivity C-reactive protein between 3 and 12 mg/l, LDL-Cholesterol ≤150 mg/dl and no previous treatment with ACE inhibitors or angiotensin receptor blockers. Ten patients, pretreated with statins, and 10 patients not previously treated with statins were eligible for statistical analysis. Baseline high-sensitivity C-reactive protein was significantly decreased from 3.99±1.61 mg/l (mean±SD) to 2.72±1.19 mg/l (–32%) after 3 months treatment with 10 mg ramipril daily (p=0.0002). The decrease was more pronounced in patients who had not been treated with statins previously (–1.50 mg/l±1.44 mg/l) compared to those who were pretreated (–0.90 mg/l±0.93 mg/l).

Conclusions

The ACE inhibitor ramipril administered in a daily dose of 10 mg to patients with atherosclerosis reduces the high-sensitivity C-reactive protein concentration. This effect may contribute to cardiovascular risk reduction mediated by ramipril aside from the blood pressure lowering effect.

Key words

High-sensitivity C-reactive protein angiotensin converting enzyme inhibitor ramipril atherosclerosis 

Einfluss des Angiotensin-Converting-Enzyme-Hemmers Ramipril auf das hochsensitive C-reaktive Protein bei Patienten mit Atherosklerose

Zusammenfassung

In den letzten Jahren konnte die Rolle des Renin-Angiotensin-Systems im Rahmen der inflammatorischen Prozesse immer besser erkannt werden. Der Einfluss einer ACE-Hemmer-Therapie auf diesen Prozess ist jedoch nicht völlig geklärt worden. Ziel dieser Studie war es, den Effekt einer Therapie mit dem ACE-Hemmer Ramipril auf hs-CRP bei Patienten mit Atherosklerose zu untersuchen.

Methoden und Ergebnisse

24 Patienten mit angiographisch gesicherter Atherosklerose wurden in diese prospektive, unkontrollierte, offene Multizenterstudie eingeschlossen. Weitere Einschlusskriterien waren ein baseline CRP-Spiegel zwischen 3 und 12 mg/l, ein LDL-Cholesterin <150 mg/dl und keine Vorbehandlung mit einem ACE-Hemmer bzw. Angiotensin-Rezeptorblocker. 10 Patienten wurden mit einem Statin vorbehandelt und 10 Patienten waren ohne begleitende Statintherapie. Vier Patienten wurden von der Analyse ausgeschlossen. Nach dreimonatiger Therapie mit 10 mg Ramipril täglich wurde das Ausgangs hs-CRP signifikant von 3,99±1,61 mg/l auf 2,72±1,19 mg/l gesenkt (p=0,0002). Der Abfall war in der Statin unbehandelten Gruppe ausgeprägter als in der Statin behandelten Gruppe (–1,50 mg/l ±1,44 mg/l versus—0,90 mg/l ±0,93 mg/l).

Schlussfolgerung

Der ACE-Hemmer Ramipril senkt in einer täglichen Dosierung von 10 mg die hoch-sensitive C-reaktive Protein-Konzentration. Dieser Effekt könnte zur der mit Ramipril erzielten kardiovaskulären Riskoreduktion über den Blutdrucksenkungseffekt hinaus beitragen.

Schlüsselwörter

Hoch-sensitives C-reaktives Protein ACE-Hemmer Ramipril Atherosklerose 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Albert MA, Danielson E, Rifai N et al (2001) Effect of statin therapy on Creactive protein levels. JAMA 286:64–70CrossRefPubMedGoogle Scholar
  2. 2.
    Andrié R, Maylahn M, Braun P, Lüderitz B, Bauriegel G (2002) C-reaktives Protein in koronarem Plaquegewebe. Z Kardiol 91:913–920CrossRefPubMedGoogle Scholar
  3. 3.
    Azar RR, Klayme S, Germanos M, Kassab R, Tawm S, Aboujaoude S, Naman R (2003) Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Am J Cardiol 92:236–239CrossRefPubMedGoogle Scholar
  4. 4.
    Brasier AR, Jamaluddin M, Han Y et al (2000) Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappa B (NF-kappaB) transcription factor. Mol Cell Biochem 212:155–159CrossRefPubMedGoogle Scholar
  5. 5.
    Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ (1996) Incresed acuumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94:2756–2767Google Scholar
  6. 6.
    Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ (1996) Incresed acuumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94:2756–2767PubMedGoogle Scholar
  7. 7.
    Di Napoli M, Papa F (2003) Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 34:2922–2929CrossRefPubMedGoogle Scholar
  8. 8.
    Fukuhara M, Geary RL, Diz DI, Gallagher PE, Wilson JA, Glazier SS, Dean RH, Ferrario CM (2000) Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 35[part 2]:353–359PubMedGoogle Scholar
  9. 9.
    Halkin A, Keren G (2002) Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med 112:126–134CrossRefPubMedGoogle Scholar
  10. 10.
    Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH (2002) Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 112:269–274CrossRefPubMedGoogle Scholar
  11. 11.
    Jialal I, Stein D, Balis D, Grungy SM, Adams-Huet B, Devaray S (2001) Effects of hydroxymethyl glutaryl Coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103:1933–1935PubMedGoogle Scholar
  12. 12.
    Koenig W, Löwel,H, Baumert J et al (2004) C-reactive protein modulates risk prediction based on the Framingham Score. Circulation 109:1349–1353CrossRefPubMedGoogle Scholar
  13. 13.
    Lonn EM, Yusuf S, Dzavik V, Doris C I, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley WA, Teo KK (2001) Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE). Circulation 103:919–925PubMedGoogle Scholar
  14. 14.
    Möckel M, Heller G Jr, Müller C, Klefisch F-R, Riehle M, Searle J, Frei U, Störk T (2000) C-reaktives Protein als unabhängiger Prognosemarker beim akuten Koronarsyndrom im Vergleich zu Troponin T. Z Kardiol 89:658–666CrossRefPubMedGoogle Scholar
  15. 15.
    Ridker PM, Rifai N, Pfeffer MA et al (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100:230–235PubMedGoogle Scholar
  16. 16.
    Ridker PM, Rifai N, Lowenthal SP (2001) Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterinemia. Circulation 103:1191–1193PubMedGoogle Scholar
  17. 17.
    Ridker PM (2003) High-sensitivity Creactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 92:17K–22KCrossRefPubMedGoogle Scholar
  18. 18.
    Ridker PM, JUPITER Study Group (2003) Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108:2292–2297CrossRefPubMedGoogle Scholar
  19. 19.
    Riesen WF, Engler H, Risch M, Korte W, Noseda G (2002) Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 23:794–799CrossRefPubMedGoogle Scholar
  20. 20.
    Schächinger V, Zeiher AM (2000) Atherosclerosis-associated endothelial dysfunction. Z Kardiol 89(Supp 9):IX/70–IX/74Google Scholar
  21. 21.
    Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harriger W, Drexler H (2000) Expression of angiotensin II and interleucin 6 in humana coronary atherosclerotic plaques. Circulation 101:1372–1378PubMedGoogle Scholar
  22. 22.
    Solheim S, Arnesen H, Eikvar L, Hurlen M, Seljeflot I (2003) Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol 92:843–845CrossRefPubMedGoogle Scholar
  23. 23.
    Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M (2003) Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 169:155–158CrossRefPubMedGoogle Scholar
  24. 24.
    The Heart Outcome Prevention Study investigators (2000) Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 342:145–153CrossRefPubMedGoogle Scholar
  25. 25.
    Verma S, Wang C-H, Li S-H, Dumond AS (2002) A self fulfilling prophecy—C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106:913–919CrossRefPubMedGoogle Scholar
  26. 26.
    Yeh ETH, Willerson JT (2003) Coming of age of C-reactive protein. Circulation 107:370–372CrossRefPubMedGoogle Scholar
  27. 27.
    Zwaka TP, Hombach V, Torzewski J (2001) C-reactive protein-mediated low density lipoprotein uptake by macrophages. Circulation 103:1194–1197PubMedGoogle Scholar

Copyright information

© Steinkopff Verlag 2005

Authors and Affiliations

  • V. Mitrovic
    • 1
  • H. H. Klein
    • 2
  • N. Krekel
    • 1
  • J. Kreuzer
    • 3
  • S. Fichtlscherer
    • 4
  • A. Schirmer
    • 5
  • W. D. Paar
    • 5
  • C. W. Hamm
    • 1
  1. 1.Kerckhoff-Klinik GmbHBad NauheimGermany
  2. 2.Klinikum Idar-Oberstein GmbH, Medizinische Klinik 2Idar-ObersteinGermany
  3. 3.St. Vincenz Krankenhaus, Medizinische Klinik, Abt. KardiologieLimburg/LahnGermany
  4. 4.Klinikum der J. W. Goethe-Universität, Medizinische Klinik IVFrankfurt am MainGermany
  5. 5.Aventis Pharma Deutschland GmbH, Medizinische Abteilung—Klinische Entwicklung, Kardiologie und ThromboseBad SodenGermany

Personalised recommendations